For the study, researchers from Rochester, Minn.-based Mayo Clinic examined clinical data on 14,865 atrial fibrillation patients compiled from October 2010 to September 2015 in a large U.S. administrative database.
Researchers determined 43 percent of atrial fibrillation patients who also suffered from severe kidney disease — which accounted for 10 percent of the study’s patient population — potentially received an overdose of blood thinner medication, which can increase the risk of severe bleeding. Among the patients without kidney disease, 13 percent may have received an underdose of the medication, possibly increasing their risk of stroke.
“We conducted this study to highlight the prevalence of inappropriate dosing in routine clinical practice and the associated adverse outcomes,” said Peter Noseworthy, MD, a Mayo Clinic cardiologist and the paper’s senior author. “This study underscores the importance for physicians to be vigilant of kidney function when selecting or adjusting dose.”
Atrial fibrillation — a common heart condition characterized by an irregular, often rapid heart rate — affects millions of Americans and is associated with a fivefold increase in stroke risk.
More articles on quality:
Hospitals in ACOs, other value-based programs perform better in readmission reduction program
Roche’s arthritis drug may be associated with hundreds of patient deaths, STAT finds
US leads other nations in health inequality: 8 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
